Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company focused on the development of novel T-cell therapies for people with cancer. The company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy a wide range of cancer types, including solid tumors. Adaptimmune is advancing a pipeline of product candidates, with a focus on becoming a fully integrated cell therapy company.
The UK headquarters serves as the central hub for global corporate leadership, core research and development activities, and strategic operations for its T-cell therapy pipeline.
Features state-of-the-art laboratory facilities, GMP-compliant manufacturing capabilities, and modern office spaces designed to foster collaboration and innovation among its scientific and operational teams.
The work culture at Adaptimmune's headquarters is characterized by a strong emphasis on scientific excellence, innovation, collaboration, and a shared commitment to patients. Employees are driven by the mission to develop transformative cancer therapies.
This location is significant due to its proximity to world-class academic institutions and a thriving biotech ecosystem, facilitating talent acquisition and scientific partnerships. It underpins Adaptimmune's research engine and global strategy.
Adaptimmune manages its global clinical trials, research collaborations, and business operations primarily from its main hubs in the United Kingdom (Abingdon, Oxfordshire) and the United States (Philadelphia, Pennsylvania). These locations support international trial sites, engagement with regulatory bodies across various countries, and foster scientific partnerships worldwide to advance its innovative T-cell therapies for cancer patients globally.
60 Jubilee Avenue, Milton Park
Abingdon
Oxfordshire
United Kingdom
Address: 351 Rouse Boulevard, Philadelphia, PA 19112, USA
To lead and support U.S. clinical trials, manage regulatory interactions with the FDA, scale up manufacturing capabilities, and prepare for potential product launches in the North American market.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Adaptimmune' leadership includes:
Adaptimmune has been backed by several prominent investors over the years, including:
Over the past 12 months, Adaptimmune has made several key leadership appointments, including a new Chief Commercial Officer and Chief Financial Officer, alongside internal promotions to Chief Scientific Officer and Chief Technology Officer. There were also notable departures including the former CFO and the retirement of a co-founder and Chief Business Officer.
Discover the tools Adaptimmune uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Adaptimmune primarily utilizes the email format consisting of the employee's first name followed by a period, then their last name, all preceding '@adaptimmune.com'. A less common, but also observed, format is the first initial of the first name followed by the last name.
first.last@adaptimmune.com
Format
jane.doe@adaptimmune.com
Example
85%
Success rate
Adaptimmune Press Release (via GlobeNewswire) • May 9, 2024
Adaptimmune provided updates on its pipeline, including progress with afami-cel towards potential BLA submission for synovial sarcoma, and its MAGE-A4 franchise. The company also reported financial results for the first quarter of 2024 and outlined key upcoming milestones....more
Adaptimmune Press Release (via GlobeNewswire) • March 7, 2024
The company highlighted significant clinical progress, including positive data for afami-cel in synovial sarcoma and advancements in its MAGE-A4 and PRAME targeted programs. Financial results for the fourth quarter and full year 2023 were also reported....more
Adaptimmune Press Release (via GlobeNewswire) • November 20, 2023
Adaptimmune announced the appointment of Gavin Wood as Chief Financial Officer, and the promotions of Dr. Joanna Brewer to Chief Scientific Officer and Dr. Mark Dudley to Chief Technology Officer, all effective January 2, 2024, to strengthen its leadership team....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Adaptimmune, are just a search away.